These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

157 related items for PubMed ID: 32544521

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Aptamer-drug conjugate: targeted delivery of doxorubicin in a HER3 aptamer-functionalized liposomal delivery system reduces cardiotoxicity.
    Dou XQ, Wang H, Zhang J, Wang F, Xu GL, Xu CC, Xu HH, Xiang SS, Fu J, Song HF.
    Int J Nanomedicine; 2018; 13():763-776. PubMed ID: 29440899
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Coupling EGFR-Antagonistic Affibody Enhanced Therapeutic Effects of Cisplatin Liposomes in EGFR-expressing Tumor Models.
    Jia D, Wang F, Yang Y, Hu P, Song H, Lu Y, Wang R, Li G, Liu R, Li J, Yuan F.
    J Pharm Sci; 2022 Feb; 111(2):450-457. PubMed ID: 34547305
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Improvement in the drug delivery and anti-tumor efficacy of PEGylated liposomal doxorubicin by targeting RNA aptamers in mice bearing breast tumor model.
    Moosavian SA, Abnous K, Badiee A, Jaafari MR.
    Colloids Surf B Biointerfaces; 2016 Mar 01; 139():228-36. PubMed ID: 26722819
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. GE11-Directed Functional Polymersomal Doxorubicin as an Advanced Alternative to Clinical Liposomal Formulation for Ovarian Cancer Treatment.
    Zou Y, Xia Y, Meng F, Zhang J, Zhong Z.
    Mol Pharm; 2018 Sep 04; 15(9):3664-3671. PubMed ID: 29570299
    [Abstract] [Full Text] [Related]

  • 11. Improved therapeutic activity of folate-targeted liposomal doxorubicin in folate receptor-expressing tumor models.
    Gabizon A, Tzemach D, Gorin J, Mak L, Amitay Y, Shmeeda H, Zalipsky S.
    Cancer Chemother Pharmacol; 2010 May 04; 66(1):43-52. PubMed ID: 19779718
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Antitumor effect of folate-targeted liposomal doxorubicin in KB tumor-bearing mice after intravenous administration.
    Riviere K, Huang Z, Jerger K, Macaraeg N, Szoka FC.
    J Drug Target; 2011 Jan 04; 19(1):14-24. PubMed ID: 20353291
    [Abstract] [Full Text] [Related]

  • 15. Enhanced doxorubicin delivery to hepatocellular carcinoma cells via CD147 antibody-conjugated immunoliposomes.
    Wang J, Wu Z, Pan G, Ni J, Xie F, Jiang B, Wei L, Gao J, Zhou W.
    Nanomedicine; 2018 Aug 04; 14(6):1949-1961. PubMed ID: 29045824
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Transferrin and octaarginine modified dual-functional liposomes with improved cancer cell targeting and enhanced intracellular delivery for the treatment of ovarian cancer.
    Deshpande P, Jhaveri A, Pattni B, Biswas S, Torchilin V.
    Drug Deliv; 2018 Nov 04; 25(1):517-532. PubMed ID: 29433357
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Intracellular delivery of doxorubicin with RGD-modified sterically stabilized liposomes for an improved antitumor efficacy: in vitro and in vivo.
    Xiong XB, Huang Y, Lu WL, Zhang X, Zhang H, Nagai T, Zhang Q.
    J Pharm Sci; 2005 Aug 04; 94(8):1782-93. PubMed ID: 15986461
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.